Twist Bioscience Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2020 Annual Meeting of Stockholders held on February 4, 2020. The registrant, Twist Bioscience Corporation, is an emerging growth company incorporated in Delaware with its principal executive offices in South San Francisco, CA. The company's common stock trades on The Nasdaq Global Select Market under the symbol TWST.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results rather than financial performance.
Material Changes and Voting Results
Approximately 56.18% of total outstanding shares eligible to be voted were present in person or by proxy (18,687,600 shares). Two proposals were voted upon:
- Proposal One (Election of Directors): Stockholders approved the election of three Class II Directors.
- Nicolas Barthelemy: Approved with 13,820,871 votes for and 666,662 votes withheld.
- Keith Crandell: Approved with 4,107,686 votes for and 10,379,847 votes withheld.
- Jan Johannessen: Approved with 10,169,909 votes for and 4,317,624 votes withheld.
- Proposal Two (Ratification of Accounting Firm): Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered accounting firm for the fiscal year ending September 30, 2021.
- Votes For: 18,671,391
- Votes Against: 8,930
- Abstentions: 7,279
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Keith Crandell received a significant number of votes withheld (10,379,847) compared to votes for (4,107,686), despite the proposal passing.
- Broker non-votes totaled 4,200,067 shares for the director election.
- PricewaterhouseCoopers LLP was ratified as the auditor for the fiscal year ending September 30, 2021.
- Shareholder participation was approximately 56.18% of eligible shares.